X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS IPCA LABS DR. DATSONS LABS/
IPCA LABS
 
P/E (TTM) x -10.9 29.6 - View Chart
P/BV x 0.2 3.5 4.6% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 DR. DATSONS LABS   IPCA LABS
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
IPCA LABS
Mar-18
DR. DATSONS LABS/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs126695 18.1%   
Low Rs31400 7.7%   
Sales per share (Unadj.) Rs133.0260.2 51.1%  
Earnings per share (Unadj.) Rs0.219.0 0.8%  
Cash flow per share (Unadj.) Rs6.633.1 20.0%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs128.8213.0 60.5%  
Shares outstanding (eoy) m31.66126.20 25.1%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.62.1 28.0%   
Avg P/E ratio x516.128.9 1,787.8%  
P/CF ratio (eoy) x11.816.6 71.5%  
Price / Book Value ratio x0.62.6 23.6%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m2,47769,120 3.6%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m567,359 0.8%   
Avg. sales/employee Rs ThNM2,477.4-  
Avg. wages/employee Rs ThNM555.2-  
Avg. net profit/employee Rs ThNM180.6-  
INCOME DATA
Net Sales Rs m4,21132,836 12.8%  
Other income Rs m79418 18.8%   
Total revenues Rs m4,28933,254 12.9%   
Gross profit Rs m5694,505 12.6%  
Depreciation Rs m2041,777 11.5%   
Interest Rs m430240 179.1%   
Profit before tax Rs m132,905 0.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6511 1.2%   
Profit after tax Rs m52,394 0.2%  
Gross profit margin %13.513.7 98.4%  
Effective tax rate %48.017.6 273.0%   
Net profit margin %0.17.3 1.6%  
BALANCE SHEET DATA
Current assets Rs m6,85219,455 35.2%   
Current liabilities Rs m6,71110,076 66.6%   
Net working cap to sales %3.328.6 11.7%  
Current ratio x1.01.9 52.9%  
Inventory Days Days16198 164.3%  
Debtors Days Days31867 475.7%  
Net fixed assets Rs m3,67320,260 18.1%   
Share capital Rs m317252 125.4%   
"Free" reserves Rs m3,76126,633 14.1%   
Net worth Rs m4,07826,886 15.2%   
Long term debt Rs m1,6712,340 71.4%   
Total assets Rs m12,63341,173 30.7%  
Interest coverage x1.013.1 7.9%   
Debt to equity ratio x0.40.1 470.8%  
Sales to assets ratio x0.30.8 41.8%   
Return on assets %3.46.4 53.8%  
Return on equity %0.18.9 1.3%  
Return on capital %7.710.8 71.3%  
Exports to sales %22.947.6 48.1%   
Imports to sales %14.314.9 96.1%   
Exports (fob) Rs m96415,642 6.2%   
Imports (cif) Rs m6024,884 12.3%   
Fx inflow Rs m96415,642 6.2%   
Fx outflow Rs m6074,884 12.4%   
Net fx Rs m35710,759 3.3%   
CASH FLOW
From Operations Rs m1,3453,411 39.4%  
From Investments Rs m-2,256-1,354 166.6%  
From Financial Activity Rs m-1,200-1,304 92.0%  
Net Cashflow Rs m-2,111753 -280.2%  

Share Holding

Indian Promoters % 4.5 45.9 9.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 11.4 -  
FIIs % 1.4 25.3 5.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 17.4 540.8%  
Shareholders   20,807 36,892 56.4%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare DR. DATSONS LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Hindustan Aeronautics IPO: Yet Another Play on India's Defence Sector (IPO)

Mar 14, 2018

Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?

Bharat Dynamics IPO: Worth Betting on Defence Manufacturing? (IPO)

Mar 12, 2018

Should you apply for the IPO of Bharat Dynamics, India's first state-owned missile manufacturer?

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - GLENMARK PHARMA COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS